Advertisement

Vitiligo pp 169-176 | Cite as

Evaluation, Assessment, and Scoring

  • Alain Taïeb
  • Mauro PicardoEmail author
Chapter

Abstract

When visiting a patient for the first time, it is necessary to take enough time in order to include a comprehensive clinical evaluation; therefore, a checklist of assessment items is useful to get a comprehensive individual image of the patient and his/her disease. The VETF scoring system combines analysis of extent, stage of disease (staging), and disease progression (spreading), and Wood’s lamp is useful for a combined assessment of staging and spreading in the same selected area. Finally, subjective items impacting quality of life are also important to take into account for management purposes.

References

  1. 1.
    Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev. 2006;(1):CD003263.Google Scholar
  2. 2.
    Anonymous. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31.CrossRefGoogle Scholar
  3. 3.
    Taïeb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20:27–35.CrossRefGoogle Scholar
  4. 4.
    Taieb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2008;360:160–9.CrossRefGoogle Scholar
  5. 5.
    Gauthier Y. The importance of Koebner’s phenomenon in the induction of vitiligo vulgaris lesions. Eur J Dermatol. 1995;5:704–8.Google Scholar
  6. 6.
    Halder RM, Grimes PE, Cowan CA, et al. Childhood vitiligo. J Am Acad Dermatol. 1987;16:948–54.CrossRefGoogle Scholar
  7. 7.
    Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16:208–14.CrossRefGoogle Scholar
  8. 8.
    Liu JB, Li M, Yang S, et al. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol. 2005;30:327–31.CrossRefGoogle Scholar
  9. 9.
    Betterle C, Caretto A, De Zio A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica. 1985;171:419–23.CrossRefGoogle Scholar
  10. 10.
    Alimohammadi M, Björklund P, Hallgren A, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med. 2008;358:1018–28.CrossRefGoogle Scholar
  11. 11.
    Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997;133:1525–8.CrossRefGoogle Scholar
  12. 12.
    Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140:677–83.CrossRefGoogle Scholar
  13. 13.
    Kunz B, Oranje AP, Labreze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10–9.CrossRefGoogle Scholar
  14. 14.
    Porter JR, Beuf AH, Lerner A, Nordlund J. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry. 1979;1:73–7.CrossRefGoogle Scholar
  15. 15.
    Kostopoulou P, Jouary T, Quintard B, et al. Objective vs subjective factors in the psychological impact of vitiligo: the experience from a French referral center. Br J Dermatol. 2009;161(1):128.CrossRefGoogle Scholar
  16. 16.
    Sampogna F, Raskovic D, Guerra L, et al. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol. 2008;159:351–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Service de DermatologieHôpital St André, CHU de BordeauxBordeauxFrance
  2. 2.Cutaneous Physiopathology and CIRM, San Gallicano Dermatological InstituteIFOItaly

Personalised recommendations